TheraRadar
Clinical-Stage Companies / Achieve Life Sciences

Achieve Life Sciences

Pre-Approval PRO BETA
20
Total Trials
8
Phase 3
4
Phase 2
0
Recruiting
184
Score

Pipeline by Phase

Phase 3
8
Phase 2
4
Phase 1
9

Therapeutic Focus

Smoking Cessation Vaping Cessation Prostate Cancer Non-Small Cell Lung Cancer Vaping

Clinical Trials (20)

NCT01630733 Phase 3 COMPLETED

A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Started: 10/24/2012

NCT07392125 Phase 3 NOT YET RECRUITING

Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes

Started: 5/15/2026

NCT04576949 Phase 3 COMPLETED

A Study of Cytisinicline for Smoking Cessation in Adult Smokers

Started: 10/13/2020

NCT05206370 Phase 3 COMPLETED

A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers

Started: 1/20/2022

NCT06435221 Phase 3 COMPLETED

Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers

Started: 5/28/2024

NCT01188187 Phase 3 COMPLETED

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer

Started: 11/1/2010

NCT01083615 Phase 3 TERMINATED

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Started: 3/1/2010

NCT01578655 Phase 3 COMPLETED

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Started: 8/1/2012

NCT05431387 Phase 2 COMPLETED

A Study of Cytisinicline for Vaping Cessation in Adult Smokers

Started: 7/13/2022

NCT03709823 Phase 2 COMPLETED

Trial of Cytisine in Adult Smokers

Started: 11/13/2018

NCT01454089 Phase 2 COMPLETED

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Started: 10/1/2011

NCT05631938 Phase 1 COMPLETED

Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose

Started: 1/10/2023

NCT05981768 Phase 1 COMPLETED

Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult Smokers

Started: 8/8/2023

NCT05566288 Phase 1 COMPLETED

Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers

Started: 10/17/2022

NCT03848208 Phase 1 COMPLETED

A Single Dose-escalation Study of Cytisine in Adult Smokers

Started: 2/28/2019

NCT03303911 Phase 1 TERMINATED

A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers

Started: 10/6/2017

NCT03509948 Phase 1 COMPLETED

A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation

Started: 4/27/2018

NCT03268343 Phase 1 COMPLETED

A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of Cytisine

Started: 8/8/2017

NCT01497470 Phase 1 COMPLETED

A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen

Started: 4/1/2012

NCT01874561 Phase 1 COMPLETED

Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization

Started: 5/1/2013

Drug Candidates

Custirsen Docetaxel Cytisinicline Placebo cytisinicline Moxifloxacin cytisine placebo Cytisine Placebo Comparator
Activity Status: Active
Last Trial Started: 5/15/2026
Last Trial Ended: 10/6/2025
Trials (12 months): 1
Completed Trials: 17
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.